FrancophonIA/ELRC3.0 huggingface dataset:
English: Further information on Aranesp can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/aranesp.
Maltese: Aktar informazzjoni dwar Aranesp tinstab fis-sit elettroniku tal-Aġenzija: ema.europa.eu/medicines/human/EPAR/aranesp.
English: Aranesp (darbepoetin alfa)
Maltese: Aranesp (darbepoetina alfa)
English: It is used in two groups of patients:
Maltese: Jintuża f'żewġ gruppi ta' pazjenti:
English: Aranesp contains the active substance darbepoetin alfa.
Maltese: Aranesp fih is-sustanza attiva darbepoetina alfa.
English: Other information about Aranesp
Maltese: Informazzjoni oħra dwar Aranesp
English: In kidney failure patients, the most common side effects with Aranesp (which may affect more than 1 in 10 people) are hypersensitivity (allergy) and hypertension (high blood pressure) while in cancer patients the most common are hypersensitivity and oedema (fluid retention).
Maltese: F'pazjenti b'insuffiċjenza tal-kliewi, l-effetti sekondarji l-aktar komuni b'Aranesp (li jistgħu jaffettwaw aktar minn persuna 1 minn kull 10) huma ipersensittività (allerġija) u ipertensjoni (pressjoni taddemm għolja) filwaqt li f'pazjenti bil-kanċer l-aktar komuni huma ipersensittività u edema (żamma talfluwidi).
English: Aranesp has also been studied in 124 children with chronic renal failure to check that it is absorbed in the same way as in adults.
Maltese: Aranesp ġie studjat ukoll f'124 tifel u tifla b'insuffiċjenza kronika tal-kliewi biex jiġi verifikat li dan hu assorbit bl-istess mod bħal fl-adulti.
English: The company that markets Aranesp will provide educational packs for patients and healthcare professionals including information on how to self-inject the medicine, a training checklist and a demonstration device.
Maltese: Il-kumpanija li tqiegħed Aranesp fis-suq ser tipprovdi pakketti edukattivi għall-pazjenti u għallprofessjonisti fil-qasam tal-kura tas-saħħa inkluż informazzjoni dwar kif il-mediċina tiġi awtoinjettata, lista ta' kontroll tat-taħriġ u apparat ta' dimostrazzjoni.
English: • adults who are receiving chemotherapy for non-myeloid cancer (cancer not originating in the bone marrow).
Maltese: • adulti li qed jieħdu kimoterapija għall-kanċer mhux tal-majelojde (kanċer li ma joriġinax fil mudullun).
English: Aranesp received a marketing authorisation valid throughout the EU on 8 June 2001.
Maltese: Aranesp ingħata awtorizzazzjoni għat-tqegħid fis-suq valida fl-UE kollha fit-8 ta' Ġunju 2001.
English: • adults and children with chronic renal failure (long-term, decreasing in the ability of the kidneys to work properly);
Maltese: • adulti u tfal li jkollhom insuffiċjenza kronika tal-kliewi (tnaqqis fit-tul fl-abbiltà tal-kliewi biex jaħdmu sew);
English: Aranesp has been shown to be effective in the treatment of chronic renal failure in four studies involving over 1,200 patients.
Maltese: Aranesp intwera li hu effettiv fil-kura ta' insuffiċjenza kronika tal-kliewi f'erba' studji li kienu jinvolvu aktar minn 1,200 pazjent.
English: Aranesp is a medicine used to treat anaemia (low red blood cell counts) that is causing symptoms.
Maltese: Aranesp huwa mediċina li tintuża għall-kura tal-anemija (għadd baxx ta' ċelloli tad-demm ħomor).
English: The dose and frequency of injection depend on why Aranesp is being used, and are adjusted, according to the patient's response, to obtain haemoglobin levels that remain within the recommended range (between 10 and 12 grams per decilitre).
Maltese: Id-doża u l-frekwenza tal-injezzjoni jiddependu mir-raġuni għaliex qed jintuża Aranesp, u jiġu aġġustati, skont ir-rispons talpazjent, biex jinkisbu livelli tal-emoglobina li jibqgħu fil-medda rakkomandata (bejn 10 grammi u 12-il gramma għal kull deċilitru).
English: As for all medicines, data on the use of Aranesp are continuously monitored.
Maltese: Bħal fil-każ tal-mediċini kollha, id-data dwar l-użu ta' Aranesp hija ssorveljata kontinwament.
English: How does Aranesp work?
Maltese: Kif jaħdem Aranesp?
English: The active substance in Aranesp, darbepoetin alfa works in exactly the same way as the natural hormone to stimulate the production of red blood cells in the bone marrow.
Maltese: Minħabba lbidliet żgħar għall-istruttura, id-darbepoetina alfa tibqa' fil-ġisem għal iktar żmien mill-eritropojetina naturali.
English: The lowest dose that provides adequate control of symptoms should be used.
Maltese: Għandha tingħata d-doża l-aktar baxxa li tipprovdi kontroll xieraq tas-sintomi.
English: For the full list of side effects and restrictions, see the package leaflet
Maltese: Għallista sħiħa tal-effetti sekondarji u r-restrizzjonijiet, ara l-fuljett ta' tagħrif.
English: In two studies involving 669 patients receiving chemotherapy, Aranesp was more effective than placebo (a dummy treatment) and fewer patients needed a blood transfusion.
Maltese: F'żewġ studji li kienu jinvolvu 669 pazjent li kienu qed jingħataw il-kimoterapija, Aranesp kien aktar effettiv mill-plaċebo (kura finta) u inqas pazjenti kienu jeħtieġu trasfużjoni tad-demm.
English: Aranesp can only be obtained with a prescription and treatment should be started by a doctor who has experience in treating the types of anaemia mentioned above.
Maltese: Aranesp jista' jinkiseb biss b'riċetta ta' tabib u l-kura għandha tinbeda minn tabib li jkollu esperjenza fil-kura tat-tipi ta' anemija msemmija hawn fuq.
English: Aranesp was as effective as human recombinant erythropoietin at increasing the haemoglobin levels and at keeping these levels maintained, whether given as an injection into a vein or under the skin.
Maltese: Aranesp kien effettiv daqs l-eritropojetina rikombinanti tal-bniedem biex iżid il-livell tal-emoglobina u biex dawn il-livelli jinżammu, sew jekk jingħata bħala injezzjoni fil-vina kif ukoll taħt il-ġilda.
English: In patients receiving chemotherapy or with kidney problems, anaemia can be caused by a lack of a hormone called erythropoietin, or by the body not responding well enough to erythropoietin.
Maltese: F'pazjenti li jkunu qed jingħataw il-kimoterapija jew li jkollhom problemi fil-kliewi, l-anemija tista' tkun ikkawżata minn nuqqas ta' ormon msejjaħ eritropojetina, jew minħabba li l-ġisem ma jkunx qed jirrispondi tajjeb biżżejjed għall-eritropojetina.
English: ProMeris Duo metaflumizone and amitraz
Maltese: ProMeris Duo metaflumizone u amitraz
English: ProMeris Duo is an ‘ectoparasiticide'.
Maltese: ProMeris Duo huwa “ektoparasitiċid” (ectoparasiticide).
English: Amitraz is a monoamine oxidase inhibitor (MOAI).
Maltese: Amitraz huwa inibitur tal-ossidażi monoamina (monoamine oxidase inhibitor - MOAI).
English: In rare cases, temporary irritation may occur at the site of application.
Maltese: F'każijiet rari, jista' jkun hemm irritazzjoni temporanja fis-sit tal-applikazzjoni.
English: The most common side effects in dogs are sedation (sleepiness), lethargy (a lack of energy), reduced nervous system activity, hyperglycaemia (high blood sugar levels), bradycardia (slow heart rate), and slow, shallow breathing.
Maltese: L-effetti sekondarji l-iktar komuni huma l-ħedla, letarġija (nuqqas ta' enerġija), attività mnaqqsa tas-sistema nervuża, ipergliċemija (livelli għoljin taz-zokkor fid-demm), bradikardija (taħbit talqalb mhux mgħaġġel), teħid tan-nifs bil-mod u mhux qawwi.
English: Dogs were treated with ProMeris Duo or the combination of imidacloprid and moxidectin (another medicine authorised in the EU for this indication).
Maltese: Il-klieb ingħataw ProMeris Duo jew kombinazzjoni ta' imidacloprid u moxidectin (mediċina oħra awtorizzata fl-UE għal din l-indikazzjoni).
English: What is the risk associated with ProMeris Duo?
Maltese: X'inhu r-riskju assoċjat ma' ProMeris Duo?
English: Why has ProMeris Duo been approved?
Maltese: Għaliex ġie approvat ProMeris Duo?
English: Another study was carried out in dogs with demodicosis in veterinary practices in Italy and Albania.
Maltese: Studju ieħor twettaq fil-klieb b'demodiċożi fil-kliniċi veterinarji fl-Italja u l-Albanija.
English: The European Commission granted a marketing authorisation valid throughout the European Union for ProMeris Duo on 19 December 2006.
Maltese: Il-Kummissjoni Ewropea tat awtorizzazzjoni għat-tqegħid fis-suq valida madwar l-Unjoni Ewropea għal ProMeris Duo fid-19 ta' Diċembru 2006.
English: The effectiveness of ProMeris Duo against flea, lice and tick infestations and Demodex mites has been studied in a number of studies, including one study in dogs infested with fleas or ticks carried out at veterinary practices in Germany and France.
Maltese: L-effikaċja ta' ProMeris Duo kontra impestazzjonijiet ta' briegħed, qamel u qurdien u dud Demodex ġiet studjata f'għadd ta' studji, inkluż studju wieħed fil-klieb li kellhom il-briegħed jew il-qurdien li twettaq fi kliniċi veterinarji fil-Ġermanja u Franza.
English: Avoid touching the skin with the pipette's contents.
Maltese: Evita li tmiss il-ġilda bil-kontenut tal-pipetta.
English: This summary was last updated on 6 January 2012.
Maltese: Dan is-sommarju ġie aġġornat l-aħħar fis-6 ta' Jannar 2012.
English: The Committee for Medicinal Products for Veterinary Use (CVMP) concluded that the benefits of ProMeris Duo exceed the risks for the treatment and prevention of flea and tick infestations, and the treatment of demodicosis and lice infestation in dogs.
Maltese: Il-Kumitat għall-Prodotti Mediċinali għall-Użu Veterinarju (CVMP) ikkonkluda li l-benefiċċji ta' ProMeris Duo huma akbar mir-riskji tiegħu fit-trattament u l-prevenzjoni ta' impestazzjonijiet ta' briegħed u qurdien, u fit-trattament tad-demodiċożi u imprestazzjoni tal-qamel fil-klieb.
English: What is ProMeris Duo?
Maltese: Kif jaħdem ProMeris Duo?
English: ProMeris Duo is a clear, yellow-to-amber solution that contains metaflumizone and amitraz as active substances.
Maltese: ProMeris Duo huwa soluzzjoni trasparenti ta' lewn isfar jagħti fl-ambra li fih is-sustanzi attivi metaflumizone u amitraz.
English: Demodicosis was usually cured within three to six months of treatment.
Maltese: Il-kura taddemodiċożi normalment tieħu bejn tlieta u sitt xhur ta' trattament.
English: It can also be used as part of a treatment strategy for the control of flea allergy dermatitis, an allergic reaction to flea bites.
Maltese: Jista' jintuża wkoll bħala parti minn strateġija ta' trattament għall-kontroll ta' dermatite allerġija tal-briegħed, reazzjoni allerġika għall-qris mill-briegħed.
English: This means that it will kill parasites that live on or in the skin or in the fur of animals, such as fleas, ticks, lice and Demodex mites (mites that cause demodicosis or ‘mange').
Maltese: Dan ifisser li joqtol il-parassiti li jgħixu fuq jew fil-ġilda jew il-pil tal-annimali, bħall-briegħed, qurdien, qamel u dud Demodex (dud li jikkawża demodiċożi jew “ġarab”).
English: Dogs of various breeds, ages and weights were treated with ProMeris Duo or with other medicines authorised in the European Union (EU) for flea and tick infestation.
Maltese: Klieb ta' diversi razez, etajiet u piżijiet ingħataw ProMeris Duo jew mediċini oħra awtorizzati fl-Unjoni Ewropea (UE) għall-impestazzjoni ta' briegħed u qurdien.
English: People taking MOAI-containing medicines, such as antidepressants, should take particular care when handling ProMeris Duo.
Maltese: Persuni li jieħdu mediċini li fihom MOAI, bħal ma huma antidepressivi, għandhom jagħtu attenzjoni partikolari fl-użu ta' ProMeris Duo.
English: Both active substances in ProMeris Duo, metaflumizone and amitraz, interfere with the neural activity of the parasites and consequently lead to their death.
Maltese: Iż-żewġ sustanzi attivi fi ProMeris Duo, metaflumizone u amitraz, jinterferixxu mal-attività tannervituri fil-parassiti u konsegwentement jirriżulta fil-mewt tagħhom.
English: ProMeris Duo is used in dogs over eight weeks of age to treat and to prevent tick and flea infestations, and to treat demodicosis (caused by Demodex mites) and lice infestations.
Maltese: Ir-riżultati tal-istudji wrew li ProMeris Duo huwa effikaċi fit-trattament u l-prevenzjoni ta' impestazzjonijiet ta' briegħed u qurdien, u fit-trattament tad-demodiċożi u impestazzjoni tal-qamel fil-klieb.
English: ProMeris Duo contains components that, on very rare occasions, can irritate the airways in some people.
Maltese: ProMeris Duo fih komponenti li, f'każijiet rari jistgħu jirritaw l-imnifsejn ta' xi nies.
English: ProMeris Duo is available in five different sizes for various weights of dog.
Maltese: ProMeris Duo huwa disponibbli f'ħames daqsijiet skont il-piż tal-kelb.
English: How has ProMeris Duo been studied?
Maltese: Kif ġie studjat ProMeris Duo?
English: In very rare cases, temporary local hair loss may occur.
Maltese: F'każijiet rari ħafna, jista' jkun hemm telf temporanju lokali tax-xagħar.
English: Ref.: EMEA/280173/2009 EMEA/H/C/1016
Maltese: EMEA/480094/2009 EMEA/H/C/1016
English: It is available as brown tablets (250 mg).
Maltese: Huwa disponibbli bħala pilloli kannella (250 mg).
English: Iressa gefitinib EPAR summary for the public
Maltese: Iressa gefitinib Sommarju tal-EPAR għall-pubbliku
English: This summary was last updated in 05-2009.
Maltese: Dan is-sommarju ġie aġġornat l-aħħar fi: 05-2009.
English: The active substance in Iressa, gefitinib, is a protein tyrosine kinase inhibitor.
Maltese: Is-sustanza attiva f'Iressa, gefitinib, hija inibitur tal-proteina tiroxina kinażi.
English: Iressa is a medicine that contains the active substance gefitinib.
Maltese: Iressa huwa mediċina li fiha s-sustanza attiva gefitinib.
English: The most common side effects with Iressa (seen in more than 1 patient in 10) are loss of appetite, diarrhoea, vomiting, nausea (feeling sick), stomatitis (inflammation of the lining of the mouth), increased level of alanine aminotransferase (a liver enzyme) in the blood, skin reactions such as pustular rash, and asthenia (weakness).
Maltese: L-effetti sekondarji l-aktar komuni b'Iressa (li dehru f'aktar minn pazjent 1 minn 10) huwa telf ta' aptit, dijarrea, remettar, nawżea (dardir), stomatite (infjammazzjoni tal-kiri tal-ħalq), żieda fil-livell ta' alanina aminotransferażi (enzima epatika) fid-demm, reazzjonijiet tal-ġilda bħal raxx pustulari u astenija (debbulizza).
English: The European Commission granted a marketing authorisation valid throughout the European Union for Iressa to AstraZeneca AB on 24 June 2009.
Maltese: Il-Kummissjoni Ewropea tat awtorizzazzjoni valida fl-Unjoni Ewropea kollha għal Iressa lil AstraZeneca AB fl-24 ta' Ġunju 2009.
English: What is Iressa?
Maltese: X'inhu Iressa?
English: In one main study involving 1,217 adult patients with locally advanced or metastatic non-small cell lung cancer, Iressa was compared with a combination of carboplatin and paclitaxel (other anticancer medicines).
Maltese: Fi studju ewlieni li involva 1,217-il pazjent adult li jsofru minn kanċer tal-pulmun mhux b'ċelloli żgħar lokalment avvanzat jew metastatiku, Iressa tqabbel ma' kombinazzjoni ta' carboplatin u paclitaxel (mediċini oħra kontra l-kanċer).
English: In a second main study involving 1,466 patients with locally advanced or metastatic non-small cell lung cancer, Iressa was compared with docetaxel (another anticancer medicine).
Maltese: Fit-tieni studju ewlieni li involva 1,466 pazjent li jsofru minn kanċer tal-pulmun mhux b'ċelloli żgħar lokalment avvanzat jew metastatiku, Iressa tqabbel ma' docetaxel (mediċina oħra kontra l-kanċer).
English: What is the risk associated with Iressa?
Maltese: X'riskji huma assoċjati ma' Iressa?
English: Why has Iressa been approved?
Maltese: Għaliex ġie approvat Iressa?
English: It is used in patients whose cancer cells have a mutation in the genes that make a protein called epidermal growth factor receptor (EGFR).
Maltese: Jintuża f'pazjenti b'ċelloli tal-kanċer b'mutazzjoni fil-ġeni li jipproduċu proteina li tissejjaħ riċettur tal-fattur tat-tkabbir epidermiku (epidermal growth factor receptor, EGFR).
English: This means that it blocks specific enzymes known as tyrosine kinases.
Maltese: Dan ifisser li timblokka xi enzimi speċifiċi magħrufa bħala tirosina kinażi.
English: In the second main study, patient survival among all patients who took Iressa was similar to those who took docetaxel.
Maltese: Fit-tieni studju ewlieni, issopravivenza tal-pazjenti fost dawk kollha ttrattati b'Iressa kienet simili għal dawk ittrattai b'docetaxel.
English: The effects of Iressa were first tested in experimental models before being studied in humans.
Maltese: L-effetti ta' Iressa għall-ewwel ġew ittestjati f'mudelli sperimentali qabel ma ġew studjati fuq ilbniedem.
English: In the first main study, Iressa was more effective at preventing the cancer from worsening than the combination.
Maltese: Fl-ewwel studju ewlieni, Iressa rriżulta aktar effikaċi fil-prevenzjoni tal-kanċer milli jaggrava milli meta mqabbel mal-kombinazzjoni.
English: The Committee for Medicinal Products for Human Use (CHMP) decided that Iressa's benefits are greater than its risks for the treatment of adults with locally advanced or metastatic non-small cell lung cancer with activating mutations of EGFR.
Maltese: Il-Kumitat għall-Prodotti Mediċinali għall-Użu mill-Bniedem (CHMP) iddeċieda li l-benefiċċji ta' Iressa huwa akbar mir-riskji tiegħu għat-trattament ta' adulti li jsofru minn kanċer tal-pulmun mhux b'ċelloli żgħar lokalment avvanzat jew metastatiku b'mutazzjonijiet li jattivaw l-EGFR. Il-Kumitat irrakkomanda li Iressa jingħata awtorizzazzjoni għat-tqegħid fis-suq.
English: There is also a risk of interstitial lung disease in patients taking Iressa.
Maltese: Hemm ukoll ir-riskju ta' marda tal-pulmin interstizjali fil-pazjenti ttrattati b'Iressa.
English: How has Iressa been studied?
Maltese: Kif ġie studjat Iressa?
English: Other information about Iressa:
Maltese: Aktar tagħrif dwar Iressa:
English: For the full list of all side effects reported with Iressa, see the Package Leaflet.
Maltese: Għal-lista sħiħa tal-effetti sekondarji kollha rrapportati ma' Iressa, ara l-Fuljett ta' Tagħrif.
English: 1 August 2017 EMA/443893/2017
Maltese: 1 ta' Awwissu 2017 EMA/443893/2017
English: The above recommendations are based on analyses of spontaneous reports of suspected adverse effects and a review of published literature.
Maltese: Ir-rakkomandazzjonijiet t'hawn fuq huma bbażati fuq analiżajiet ta' rapporti spontanji ta' effetti avversi suspettati u reviżjoni ta' letteratura ppubblikata.
English: • Lactose of bovine origin is used as an excipient in some injectable methylprednisolone-containing products.
Maltese: • Il-lattożju ta' oriġini bovina huwa użat bħala eċċipjent f'xi prodotti injettabbli li fihom methylprednisolone.
English: The review of injectable medicines for acute allergic reaction that contain lactose from cows' milk was initiated on 1 December 2016 at the request of Croatia, under Article 31 of Directive 2001/83/EC.
Maltese: Ir-reviżjoni tal-mediċini injettabbli għal reazzjoni allerġika akuta li fihom il-lattożju minn ħalib tal-baqra bdiet fl-1 ta' Diċembru fuq talba tal-Kroazja, skont l-Artikolu 31 tad-Direttiva 2001/83/KE.
English: 1 The Co-ordination Group for Mutual Recognition and Decentralised Procedures - Human (CMDh) is a medicines regulatory body representing the European Union (EU) Member States, as well as Iceland, Liechtenstein and Norway.
Maltese: 1 Il-Grupp ta' Koordinazzjoni għal Proċedura tar-Rikonoxximent Reċiproku u l-Proċedura Deċentralizzata - Bniedem (CMDh) huwa korp regolatorju tal-mediċini li jirrappreżenta l-Istati Membri tal-Unjoni Ewropea (UE), kif ukoll l-Iżlanda, ilLiechtenstein u n-Norveġja.
English: The review of these medicines was triggered following reports of serious allergic reactions such as bronchospasm (excessive contraction of the airway muscles causing breathing difficulty) and anaphylaxis (sudden severe allergic reaction) with these medicines in patients allergic to cow's milk proteins.
Maltese: Ir-reviżjoni ta' dawn il-mediċini ġiet ikkawżata wara rapporti ta' reazzjonijiet allerġiċi serji bħall-bronkospażmu (kontrazzjoni eċċessiva tal-muskoli talpassaġġ tal-arja li tikkawża diffikultà fin-nifs) u anafilassi (reazzjoni allerġika severa f'daqqa) b'dawn ilmediċini f'pazjenti allerġiċi għall-proteini tal-ħalib tal-baqra.
English: Methylprednisolone-containing medicines have been authorised by national procedures for use by injection into a vein or muscle and have been available for many years in the EU under a variety of brand names including Solu-Medrol.
Maltese: Mediċini li fihom methylprednisolone ġew awtorizzati minn proċeduri nazzjonali għall-użu minn injezzjoni fil-vina jew filmuskolu u ilhom disponibbli għal ħafna snin fl-UE taħt varjetà ta' ismijiet tad-ditta inkluż Solu-Medrol.
English: Companies have been asked to provide data allowing the replacement of formulations containing lactose from cow's milk; this data should be provided by the middle of 2019.
Maltese: Il-kumpaniji ġew mitluba jipprovdu data li tippermetti s-sostituzzjoni ta' formulazzjonijiet li fihom lattożju mill-ħalib tal-baqra; din id-data għandha tiġi pprovduta sa nofs l
English: The CMDh1 has endorsed the recommendation of EMA's Pharmacovigilance Risk Assessment Committee (PRAC) that methylprednisolone injections containing lactose (milk sugar), which potentially contain traces of cow's milk proteins, must not be used in patients with a known or suspected allergy to the proteins in cow's milk.
Maltese: Is-CMDh1 approva r-rakkomandazzjoni tal-Kumitat dwar il-Valutazzjoni tar-Riskji tal-Farmakoviġilanza (PRAC) tal-EMA li l-injezzjonijiet tal-methylprednisolone li fihom il-lattożju (zokkor tal-ħalib), li potenzjalment ikun fihom traċċi tal-proteini tal-ħalib tal-baqra, m'għandhomx jintużaw f'pazjenti b'allerġija magħrufa jew suspettata għall-proteini fil-ħalib tal-baqra.
English: Corticosteroids are anti-inflammatory medicines used to control the immune system (the body's natural defences) when it is overactive, as in allergic conditions.
Maltese: Kortikosteroidi huma mediċini anti-infjammatorji użati biex jikkontrollaw is-sistema immunitarja (iddifiżi naturali tal-ġisem) meta din hija attiva żżejjed, kif ukoll f'kundizzjonijiet allerġiċi.
English: • Serious allergic reactions, including bronchospasm and anaphylaxis, were reported in patients allergic to cow's milk proteins who were treated for acute allergic conditions with these medicines.
Maltese: • Reazzjonijiet allerġiċi serji, inklużi bronkospażmu u anafilassi, ġew irrappurtati f'pazjenti allerġiċi għall-proteini tal-ħalib tal-baqra li ġew ikkurati għal kundizzjonijiet allerġiċi akuti b'dawn ilmediċini.
English: In some of the reported cases the adverse reaction was misinterpreted as a lack of therapeutic effect, leading to re-administration of methylprednisolone and subsequent worsening of the patient's clinical condition.
Maltese: F'xi każijiet irrappurtati, ir-reazzjoni avversa ġiet interpretata ħażin bħala nuqqas ta' effett terapewtiku, li twassal għal amministrazzjoni mill-ġdid ta' methylprednisolone u aggravament sussegwenti tal-kundizzjoni klinika tal-pazjent.
English: • If you are allergic to cow's milk proteins and you require methylprednisolone, your doctor will use a methylprednisolone medicine that does not contain lactose or use an alternative medicine.
Maltese: • Għall-pazjenti allerġiċi għall-proteini tal-ħalib tal-baqra li jeħtieġu methylprednisolone, iqisu preparazzjonijiet li ma fihomx lattożju jew jużaw kuri alternattivi.
English: • Methylprednisolone injections containing lactose of bovine origin are now contraindicated in patients known or suspected to be allergic to cow's milk proteins.
Maltese: • Injezzjonijiet tal-methylprednisolone li fihom lattożju ta' oriġini bovina issa huma kontraindikati f'pazjenti li għandhom allerġija jew għandhom suspett li huma allerġiċi għall-proteini tal-ħalib talbaqra.
English: The review covered certain injectable medicines which contain the corticosteroid methylprednisolone and are used to treat the symptoms of severe allergic reactions and other inflammatory conditions.
Maltese: Ir-reviżjoni kopriet ċerti mediċini injettabbli li fihom methylprednisolone kortikosterojde u huma użati sabiex jikkuraw is-sintomi ta' reazzjonijiet allerġiċi severi u kundizzjonijiet infjammatorji oħrajn.